Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 4/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
| ▸ | SORD | Q00796 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933293 | 0.90 | EIF2AK4 (0.39) | EIF2AK4HSD11B1SLC6A7SORDPIK3CD | |
| SCHEMBL8985979 | 0.88 | EIF2AK4 (0.38) | EIF2AK4HSD11B1SORDPIK3CDSCN9A | |
| SCHEMBL8987864 | 0.86 | EIF2AK4 (0.38) | EIF2AK4HSD11B1SLC6A7SORD | |
| SCHEMBL12341821 | 0.86 | EIF2AK4 (0.37) | EIF2AK4HSD11B1SORD | |
| SCHEMBL8987784 | 0.85 | EIF2AK4 (0.38) | EIF2AK4HSD11B1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL8989305 | 0.85 | HSD11B1 (0.40) | EIF2AK4HSD11B1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL8990242 | 0.85 | EIF2AK4 (0.37) | EIF2AK4HSD11B1SLC6A7 | |
| SCHEMBL8990365 | 0.84 | EIF2AK4 (0.36) | EIF2AK4HSD11B1SORDHCAR2WNT3A | |
| SCHEMBL8988012 | 0.84 | JAK3 (0.38) | EIF2AK4WNT3A | |
| SCHEMBL8987899 | 0.83 | PIK3CD (0.38) | EIF2AK4HSD11B1CACNA1GCACNA1HCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | EIF2AK4 462/4885HSD11B1 4216/4885CACNA1G 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.